Reported Earnings • Mar 04
Third quarter 2026 earnings released: CA$0.004 loss per share (vs CA$0 in 3Q 2025) Third quarter 2026 results: CA$0.004 loss per share (further deteriorated from CA$0 in 3Q 2025). Net loss: CA$380.3k (loss widened 14% from 3Q 2025). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has increased by 51% per year, which means it is tracking significantly ahead of earnings growth. Tillkännagivande • Jan 16
Biomark Diagnostics Inc. Announces Publication of Peer-Reviewed Validation of Machine Learning Models for Lung Cancer Detection in Frontiers in Oncology BioMark Diagnostics Inc. announced that its long-term investment in integrating artificial intelligence and machine learning into metabolomic profiling has achieved a major milestone. As the global healthcare investment community is focused on the transformative power of AI at the J.P. Morgan Healthcare Conference, BioMark has received this week notification that its research regarding a machine learning-driven predictive model for lung cancer detection has been accepted for publication in the prestigious, peer-reviewed journal Frontiers in Oncology. The accepted article, titled "Translational impact of machine learning-driven predictive modeling with pathway-based plasma metabolomic biomarkers for lung cancer detection," represents a successful realization of BioMark's strategy to utilize advanced computational tools to enhance diagnostic precision. This achievement validates the company's past capital allocation toward sophisticated AI infrastructure and confirms the scientific rigor of its metabolic pathway analysis. By moving beyond traditional biomarker identification and utilizing pathway-level data, BioMark has demonstrated a more comprehensive way to interpret the metabolic signatures of early-stage lung cancer. This research was made possible through a strategic collaboration with Dr. Maria Vaida and her team at the Harrisburg University of Science and Technology. The publication describes the use of pathway-based features from the Human Metabolome Database (HMDB) and explores the mechanistic drivers of cancer through interpretability tools such as SHAP analysis. This methodological approach allows for a deeper understanding of how specific metabolic pathways, such as those involved in nutrient processing and tumor growth, contribute to diagnostic models. The partnership with Harrisburg University has been instrumental in bridging the gap between complex data science and clinical application, ensuring that BioMark's technological foundation is built upon peer-reviewed, world-class scientific inquiry. Tillkännagivande • Jan 01
Biomark Diagnostics Inc. Appoints James Lavender as Board of Director, Effective December 22, 2025 BioMark Diagnostics Inc. has appointed Mr. James Lavender to its Board of Directors following resolutions from the Annual General Meeting held on December 22, 2025. Mr. Lavender and his group were major investors in BioMark's most recent financing, completed in March 2025, underscoring strong insider alignment with the Company's growth strategy as it transitions from development to commercial execution. As BioMark accelerates its U.S. market entry, Mr. Lavender has been instrumental in opening high-level channels with state-level organizations and strategic investment groups across the United States. Mr. Lavender brings extensive software development and enterprise sales experience from leading technology companies, with a particular focus on scaling data-driven platforms. He has been a key advocate for expanding BioMark's use of Artificial Intelligence (AI) and Machine Learning (ML) to enhance clinical performance, automation, and scalability of metabolomics-based oncology diagnostics. Reported Earnings • Nov 30
Second quarter 2026 earnings released: CA$0.005 loss per share (vs CA$0.006 loss in 2Q 2025) Second quarter 2026 results: CA$0.005 loss per share (improved from CA$0.006 loss in 2Q 2025). Net loss: CA$481.4k (loss narrowed 12% from 2Q 2025). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has increased by 26% per year, which means it is tracking significantly ahead of earnings growth. Tillkännagivande • Oct 14
Biomark Diagnostics Inc., Annual General Meeting, Dec 22, 2025 Biomark Diagnostics Inc., Annual General Meeting, Dec 22, 2025. Reported Earnings • Aug 31
First quarter 2026 earnings released: CA$0.004 loss per share (vs CA$0.007 loss in 1Q 2025) First quarter 2026 results: CA$0.004 loss per share (improved from CA$0.007 loss in 1Q 2025). Net loss: CA$416.0k (loss narrowed 33% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 14% per year whereas the company’s share price has increased by 15% per year. Reported Earnings • Jul 29
Full year 2025 earnings released: CA$0.021 loss per share (vs CA$0.017 loss in FY 2024) Full year 2025 results: CA$0.021 loss per share (further deteriorated from CA$0.017 loss in FY 2024). Net loss: CA$1.93m (loss widened 35% from FY 2024). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth. Tillkännagivande • May 12
Biomark Diagnostics Inc. Announces the Publication of Pivotal Study as Part of the Special Issue Molecular Pathogenesis and Diagnostics of Lung Diseases of the International Journal of Molecular Sciences BioMark Diagnostics Inc. announced the publication of a pivotal study as part of the special issue Molecular Pathogenesis and Diagnostics of Lung Diseases of the International Journal of Molecular Sciences. The research, titled "Clinical Validation of Plasma Metabolite Markers for Early Lung Cancer Detection", provides significant external validation for BioMark's metabolomics and machine learning powered technology, particularly highlighting its high specificity and accuracy in detecting early-stage non-small cell lung cancer (NSCLC) and differentiating it from other non-cancerous lung conditions. The study utilized a large, clinically diverse patient cohort, analyzing 680 archived plasma samples in a discovery cohort and an independent set of 216 plasma samples for validation. A key strength of the research was the composition of the control group, which included not only healthy individuals but also patients with various non-cancerous lung diseases. This design allowed for a rigorous assessment of the test's ability to accurately identify lung cancer, minimizing the potential for false positives due to other lung conditions. The ability to detect lung cancer at its earliest stages significantly improves patient outcomes and survival rates. Current screening methods, such as low dose computed tomography (LDCT), have limitations, including lower sensitivity and specificity compared to regular CT scans, and can result in false positives leading to unnecessary invasive procedures. BioMark's minimally invasive blood test offers a promising approach to complement current screening methods, potentially leading to earlier interventions and better patient prognoses. New Risk • Apr 03
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 16% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Negative equity (-CA$1.1m). Earnings have declined by 11% per year over the past 5 years. Revenue is less than US$1m (CA$155k revenue, or US$110k). Minor Risks Shareholders have been diluted in the past year (16% increase in shares outstanding). Market cap is less than US$100m (CA$24.8m market cap, or US$17.7m). Tillkännagivande • Mar 31
Biomark Diagnostics Inc. announced that it has received CAD 4.261195 million in funding On March 31, 2025, BioMark Diagnostics Inc. closed the transaction. The company announced that it has issued 4,593,984 units at an issue price of CAD 0.30 per unit for gross proceeds of CAD 1,378,195.2 in second and final tranche. The Units were issued at a price of CAD 0.30 per Unit, for aggregate gross proceeds of CAD 4,261,195. Each unit consists of one common share and one full purchase warrant. One whole share purchase warrant will entitle the holder thereof to purchase one common share at CAD 0.50 per share for a period of three years from the closing date of the private placement. The securities issued under the private placement will be subject to a period of four months and one day under the Canadian securities laws and subject to resale restrictions under the U.S. securities laws. Certain Insiders, Directors and Officers subscribed for a portion of this placement. Participation of the insiders of the Company in the private placement. The transaction included participation from United States and Europe. The transaction is oversubscribed. Tillkännagivande • Mar 27
Biomark Diagnostics Inc. announced a financing transaction Biomark Diagnostics Inc. announced a non-brokered private placement that it will issue units to receive funding on March 26, 2025. Each unit consists of one common share of company and one full purchase warrant. One whole share purchase warrant will entitle the holder thereof to purchase one common share at CAD 0.50 per share for a period of three years from the closing date of the private placement. The securities issued under the private placement will be subject to a period of four months and one day under the Canadian securities laws and subject to resale restrictions under the U.S. securities laws. No finders' fees were payable on the private placement. Under the first tranche, the company issued 9,610,000 units at a price of CAD 0.30 per Unit, for aggregate gross proceeds of CAD 2,883,000. Reported Earnings • Mar 02
Third quarter 2025 earnings released: EPS: CA$0 (vs CA$0.005 loss in 3Q 2024) Third quarter 2025 results: EPS: CA$0 (improved from CA$0.005 loss in 3Q 2024). Revenue: CA$38.6k (down 7.2% from 3Q 2024). Net loss: CA$334.8k (loss narrowed 18% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has remained flat, which means it is significantly lagging earnings. Reported Earnings • Dec 01
Second quarter 2025 earnings released: CA$0.006 loss per share (vs CA$0.003 loss in 2Q 2024) Second quarter 2025 results: CA$0.006 loss per share (further deteriorated from CA$0.003 loss in 2Q 2024). Revenue: CA$38.3k (down 9.0% from 2Q 2024). Net loss: CA$547.3k (loss widened 160% from 2Q 2024). Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 8% per year, which means it is performing significantly worse than earnings. New Risk • Nov 24
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: CA$13.0m (US$9.32m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$1.1m free cash flow). Negative equity (-CA$650k). Earnings have declined by 15% per year over the past 5 years. Revenue is less than US$1m (CA$162k revenue, or US$116k). Market cap is less than US$10m (CA$13.0m market cap, or US$9.32m). Minor Risk Shareholders have been diluted in the past year (9.1% increase in shares outstanding). Tillkännagivande • Oct 21
Biomark Diagnostics Inc., Annual General Meeting, Dec 27, 2024 Biomark Diagnostics Inc., Annual General Meeting, Dec 27, 2024. Location: british columbia, richmond Canada Tillkännagivande • Sep 10
Biomark Diagnostics Completes Testing of over 5,400 Subjects as Part of A Validation Study for Early Lung Cancer Detection BioMark Diagnostics Inc. announced the successful completion of a significant clinical trial in collaboration with the Institut Universitaire de Cardiologie et de Pneumologie de Quebec. Over 5,400 patient samples were analyzed using BioMark's innovative lung cancer assay, demonstrating the test's potential to revolutionize early detection and improve patient outcomes. BioMark has partnered with a leading data analytics group possessing robust artificial intelligence and machine learning capabilities to analyze the vast amount of data collected during the trial. The results of the study will be presented at an upcoming medical conference and submitted for publication in a peer-reviewed journal. BioMark is committed to advancing the development of its lung cancer assay and making it available to patients in need as soon as possible. This innovative technology has the potential to significantly improve early detection rates and treatment outcomes for this devastating disease. Reported Earnings • Aug 30
First quarter 2025 earnings released: CA$0.007 loss per share (vs CA$0.005 loss in 1Q 2024) First quarter 2025 results: CA$0.007 loss per share (further deteriorated from CA$0.005 loss in 1Q 2024). Revenue: CA$38.3k (down 3.6% from 1Q 2024). Net loss: CA$623.3k (loss widened 49% from 1Q 2024). Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings. Reported Earnings • Jul 28
Full year 2024 earnings released: CA$0.017 loss per share (vs CA$0.022 loss in FY 2023) Full year 2024 results: CA$0.017 loss per share (improved from CA$0.022 loss in FY 2023). Revenue: CA$163.2k (up 6.3% from FY 2023). Net loss: CA$1.43m (loss narrowed 23% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings. New Risk • Jul 26
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$946k free cash flow). Negative equity (-CA$560k). Earnings have declined by 21% per year over the past 5 years. Revenue is less than US$1m (CA$163k revenue, or US$118k). Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Shareholders have been diluted in the past year (9.1% increase in shares outstanding). Market cap is less than US$100m (CA$16.8m market cap, or US$12.1m). New Risk • Mar 03
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$946k This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$946k free cash flow). Negative equity (-CA$560k). Earnings have declined by 21% per year over the past 5 years. Revenue is less than US$1m (CA$163k revenue, or US$120k). Minor Risks Shareholders have been diluted in the past year (9.1% increase in shares outstanding). Market cap is less than US$100m (CA$23.2m market cap, or US$17.1m). Reported Earnings • Mar 03
Third quarter 2024 earnings released: CA$0.005 loss per share (vs CA$0.005 loss in 3Q 2023) Third quarter 2024 results: CA$0.005 loss per share (in line with 3Q 2023). Revenue: CA$41.5k (up 13% from 3Q 2023). Net loss: CA$406.8k (loss widened 3.3% from 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 13% per year whereas the company’s share price has fallen by 11% per year. Board Change • Feb 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 3 highly experienced directors. Member of Advisory Board AI Berkeley was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. New Risk • Jan 05
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 10% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Negative equity (-CA$1.2m). Earnings have declined by 23% per year over the past 5 years. Revenue is less than US$1m (CA$159k revenue, or US$119k). Minor Risks Shareholders have been diluted in the past year (10% increase in shares outstanding). Market cap is less than US$100m (CA$19.9m market cap, or US$14.9m). Tillkännagivande • Dec 29
Biomark Diagnostics Inc. announced that it has received CAD 1.9 million in funding Biomark Diagnostics Inc announced that it has completed a non-brokered private placement of 7,600,000 units at a price of CAD 0.25 per unit for gross proceeds of CAD 1,900,000 on December 29, 2023. The securities issued under the private placement will be subject to a hold period of four months and one day. Each unit consists of one common share and one-full purchase warrant. One whole share purchase warrant will entitle the holder thereof to purchase one common share at CAD 0.45 per share for a period of three years from the closing date of the private placement, subject to an acceleration clause. Certain Insiders, Directors and Officers subscribed for a portion of this placement. No Finders' fees were payable on the private placement. Reported Earnings • Nov 30
Second quarter 2024 earnings released: CA$0.003 loss per share (vs CA$0.006 loss in 2Q 2023) Second quarter 2024 results: CA$0.003 loss per share (improved from CA$0.006 loss in 2Q 2023). Revenue: CA$42.1k (up 2.9% from 2Q 2023). Net loss: CA$210.5k (loss narrowed 60% from 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has increased by 29% per year, which means it is well ahead of earnings. Tillkännagivande • Oct 13
Biomark Diagnostics Inc., Annual General Meeting, Dec 22, 2023 Biomark Diagnostics Inc., Annual General Meeting, Dec 22, 2023. New Risk • Aug 04
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: CA$12.9m (US$9.65m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$920k free cash flow). Negative equity (-CA$1.1m). Earnings have declined by 25% per year over the past 5 years. Revenue is less than US$1m (CA$153k revenue, or US$115k). Market cap is less than US$10m (CA$12.9m market cap, or US$9.65m). Minor Risk Share price has been volatile over the past 3 months (14% average weekly change). Reported Earnings • Aug 01
Full year 2023 earnings released: CA$0.022 loss per share (vs CA$0.02 loss in FY 2022) Full year 2023 results: CA$0.022 loss per share (further deteriorated from CA$0.02 loss in FY 2022). Revenue: CA$153.5k (up 249% from FY 2022). Net loss: CA$1.84m (loss widened 27% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has only fallen by 10% per year, which means it has not declined as severely as earnings. New Risk • Jul 22
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 14% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$1.2m free cash flow). Negative equity (-CA$870k). Earnings have declined by 24% per year over the past 5 years. Revenue is less than US$1m (CA$138k revenue, or US$104k). Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Market cap is less than US$100m (CA$22.2m market cap, or US$16.8m). Tillkännagivande • Jan 12
BioMark Diagnostics Inc. Announces Update from Ongoing Clinical Trial Using its Lung Cancer Liquid Biopsy Test as it Prepares for Commercial Launch BioMark Diagnostics Inc. announced several updates from ongoing clinical trial using the Company's liquid biopsy test for early cancer detection and monitoring of lung cancer. As clinical trial success relies on effective patient recruitment, BioMark is delighted to announce that enrollment for its pivotal lung cancer screening study exceeded 1,000 participants in less than one year. The lung cancer screening demonstration project led by Dr. Simon Martel, pulmonologist at the Quebec Heart and Lung Institute (Institut Universitaire de Cardiologie et Pneumologie de Québec- Université Laval - IUCPQ-UL), is intended to combine BioMark's metabolomics liquid biopsy test with radiomics and genetics biomarkers to help at-risk Quebecers get access to an accurate and accessible lung cancer screening program. The multimodal study was designed to recruit 4,000 participants from eight major hospitals across in Quebec, generating data that can support BioMark's implementation within the Province of Quebec. The Company also announces its first international patient recruited as part of a European prospective lung cancer screening trial in France known as the ILYAD study. BioMark's blood-based biomarker panel has been selected to define personalized lung cancer risk assessment in Europe's screen-eligible population who are most likely to benefit from a CT scan. The study is being conducted by Pr Sébastien Couraud, pulmonologist at the Hospices Civils de Lyon (HCL) and through a partnership with France- based TransDiag. Through the ILYAD study, the investigators are studying the participation rate during the initial round in the lung cancer screening program and assessing the performance of several blood- based biomarkers for the detection of cancers in screened individuals. The test being developed by the consortium would offer the opportunity to screen nearly 4 million individuals in France who are eligible for lung cancer screening under current European guidelines. These at-risk individuals are aged between 50 and 75 and have a history of heavy smoking. The Company intends to pursue clinical validation of the test as a laboratory developed test (LDT) in parallel with these ongoing studies. The BioMark Lung Cancer Risk Assessment Test will be available through its Quebec-based accredited laboratory, BioMark Diagnostic Solutions Inc., within approximately 9 - 12 months based on the completion of the ISO 15-189 certification. Tillkännagivande • Oct 29
Biomark's Glioblastoma Study Published in Cancers Demonstrates Inhibiting SAT1 Sensitized Cancer Cells Towards Radiation and Chemotherapy BioMark Diagnostics Inc. announce the publication of a preclinical study demonstrating therapeutic capabilities of its SAT1 cancer marker in glioblastoma (GB) cells using an ionizable lipid nanoparticle. The study published as part of the special issue of Cancers "Novel Techniques and Technology for Treatment of Brain Tumors", reports that Spermidine/spermine N1-acetyltransferase 1 (SAT1) inhibition using an ionizable lipid nanoparticle-based siRNA delivery system appears to provide a safe and effective method to sensitizing GB cells to radiation and chemotherapeutic agents. Glioblastoma is an aggressive form of brain cancer with no effective cure. The current treatment for GB involves surgical removal of the tumor followed by chemotherapy and radiation therapy. However, GB develops chemo and radiation therapy resistance, leading to tumor recurrence. GB cells, in comparison to normal cells, have high metabolic rates and adapt several cell signaling pathways to promote their survival. With current treatments, the median survival time of patients is 15 months. There is great need to investigate novel strategies to treat GB and effectively monitor response to treatment. Hence, identifying and inhibiting these tumor protecting pathways can be helpful to manage GB therapy better. Tillkännagivande • Oct 08
BioMark Diagnostics Inc., Annual General Meeting, Dec 20, 2022 BioMark Diagnostics Inc., Annual General Meeting, Dec 20, 2022. Tillkännagivande • May 05
BioMark Diagnostics Inc. announced that it has received CAD 1.2655 million in funding Biomark Diagnostics Inc announced closing of a non-brokered private placement of 5,062,000 units at a price of CAD 0.25 per unit for gross proceeds of CAD 1,265,500 on May 4, 2022. Each unit consists of one common share and one-full purchase warrant. Each whole warrant will entitle the holder to acquire one common share at an exercise price of CAD 0.45 per share for a period of two years from the closing date of the private placement, subject to an acceleration clause. The securities issued under the transaction will be subject to a hold period of four months and one day. The transaction included participation from certain insiders, directors and officers. Tillkännagivande • Jul 01
Biomark Diagnostics Inc to Expand Treatment Response Trial to Advanced Lung Cancer Patients Receiving Immunotherapy BioMark Diagnostics Inc. announced that Health Canada has approved its clinical trial application (CTA) and has granted a Letter of No Objection (NOL) for its application entitled Excretion of Acetylamantadine (AA) by Lung Cancer Patients During a Chemotherapy Regimen With or Without Immunotherapy. Since immunotherapy is now standard of care for lung cancer, BioMark amended the protocol to include study participants receiving immunotherapy and added the Institut Universitaire de Cardiologie et de Pneumologie de Québec (IUCPQ) as an additional site under the supervision of Dr Philippe Joubert. The amended protocol is intended to test the hypothesis that downregulation of SSAT1 activity as reflected by a reduced plasma concentration of acetylamantadine, will occur earlier than can be detected by other diagnostic testing methods used to determine the efficacy of chemotherapy combined or not to immunotherapy in patients with a diagnosis of stage III lung cancer. This amendment approval from Health Canada will facilitate the study and permit achieving the required sample size in a timely manner. Patient recruitment is anticipated to commence later in the 3rd quarter. This study on lung cancer patients is a follow-up to a previous study performed to determine the urinary levels of AA in normal healthy volunteers and in patients with a cancer diagnosis. Is New 90 Day High Low • Feb 27
New 90-day high: CA$0.26 The company is up 100% from its price of CA$0.13 on 26 November 2020. The Canadian market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 8.0% over the same period. Tillkännagivande • Feb 18
BioMark Diagnostics Inc.'s Subsidiary BioMark Diagnostic Solutions Inc. Enters into Collaborative Research and Development Agreement with Phytronix Technologies Inc BioMark Diagnostics Inc. announced that its wholly-owned subsidiary BioMark Diagnostic Solutions Inc. has entered into a collaborative research and development agreement with Phytronix Technologies Inc. to advance the development of BioMark's early lung cancer screening applications using Phytronix-proprietary Laser Diode Thermal Desorption technology. While BioMark Diagnostic Solutions is preparing to offer lab services and metabolomics capabilities in Quebec City to accelerate commercialization of its assays, the Quebec-based Phytronix will bring its experience in high-throughput analysis, automated sample preparation and assay development to this collaboration. Is New 90 Day High Low • Feb 05
New 90-day high: CA$0.22 The company is up 47% from its price of CA$0.15 on 06 November 2020. The Canadian market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 21% over the same period. Tillkännagivande • Jan 12
Alfred Berkeley Joins BioMark Diagnostics Inc.'s Advisory Team BioMark Diagnostics Inc. announced Alfred Berkeley as a new member of the BioMark's Advisory team, as he will be providing strategic and financial advice to help expand the company's commercialization effort in the U.S. Mr. Alfred Rives Berkeley, III, has over 40 years of experience in the financial industry, and currently serves as the Chairman at Princeton Capital Management Inc., since January 2013. 